<DOC>
	<DOCNO>NCT00134069</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose sorafenib give together cetuximab irinotecan see well work treat patient advanced metastatic colorectal cancer . Sorafenib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Sorafenib cetuximab may also stop tumor growth block blood flow tumor . Drugs use chemotherapy , irinotecan , work different way kill tumor cell , either kill cell stop divide . Giving sorafenib together cetuximab irinotecan may kill tumor cell</brief_summary>
	<brief_title>Sorafenib , Cetuximab , Irinotecan Treating Patients With Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity spectrum dose-limiting toxic effect sorafenib combine cetuximab irinotecan patient advance metastatic colorectal cancer . II . Determine recommend phase II dose sorafenib combine cetuximab irinotecan patient . III . Correlate clinical activity regimen , term radiologic positron emission tomography ( PET ) response , baseline extracellular signal-regulated kinase ( ERK ) expression well Kirsten rat sarcoma ( KRAS ) , BRAF , genetic property tumor patient . IV . Determine pharmacokinetics regimen patient . V. Correlate pharmacodynamic effect regimen baseline ERK expression well KRAS , BRAF , genetic property tumor patient . VI . Correlate pharmacodynamic effect regimen mitogen-activated protein kinase ( MAPK ) status peripheral blood mononuclear cell normal skin oral mucosa clinical parameter patient . OUTLINE : This phase I dose-escalation study sorafenib follow multicenter phase II study . PHASE I : COURSE 1 ( 56 day ) : Patients receive oral sorafenib twice daily day 1-56 , cetuximab IV 1-2 hour day 1 , 8,15 , 22 , 29 , 36 , 43 , 50 , irinotecan IV 90 minute day 15 , 22 , 29 , 36 . COURSE 2 AND ALL SUBSEQUENT COURSES ( 42 day ) : Patients receive oral sorafenib twice daily day 1-42 , cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 36 , irinotecan IV 90 minute day 1 , 8 , 15 , 22 . Courses repeat every 42 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos sorafenib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . PHASE II : Patients receive sorafenib MTD determine phase I , cetuximab , irinotecan phase I . After completion study treatment , patient follow 30 day . *NOTE : This trial intend Phase I/II , trial never continue Phase II portion .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm colorectal cancer ( advanced metastatic disease amenable potential curative resection ) Archival tumor ( block and/or slide ) must available patient decline tumor biopsy Tumor must amenable sequential biopsy patient willing undergo tumor biopsy Must evidence disease progression firstline chemotherapy advance disease Previously irradiate lesion consider measurable disease Measurable disease , define &gt; = 1 unidimensionally measurable target lesion &gt; = 20 mm conventional technique OR &gt; = 10 mm spiral CT scan No known brain metastasis Eastern Cooperative Oncology Group ( ECOG ) 02 OR Karnofsky 60100 % Life expectancy 12 week white blood cell count ( WBC ) &gt; = 3,000/mm^3 Bilirubin normal Creatinine normal OR creatinine clearance &gt; = 60 mL/min No hypertension No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Able swallow oral medication Willing undergo 2 sequential tumor skin biopsies No ongoing active infection No history allergic reaction attribute compound similar chemical biologic composition study drug No psychiatric illness social situation would preclude study compliance No uncontrolled illness No prior cetuximab No concurrent prophylactic filgrastim ( GCSF ) , sargramostim ( GMCSF ) epoetin alfa At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy More 4 week since prior radiotherapy recover No prior sorafenib No prior therapy target MAPK More 14 day since prior concurrent administration follow cytochrome P450 3A4 ( CYP3A4 ) inducer : Rifampin Rifabutin Hypericum perforatum ( St. John 's wort ) Phenytoin Carbamazepine Phenobarbital More 7 day since prior concurrent administration follow CYP3A4 inhibitor : Amiodarone Clarithromycin Diltiazem Erythromycin Grapefruit juice Indinavir Saquinavir Lopinavir combination ritonavir Fosamprenavir Ritonavir Atazanavir Nelfinavir Itraconazole Ketoconazole Nefazodone No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer therapy Negative pregnancy test Fertile patient must use effective contraception Absolute neutrophil count &gt; =1,500/mm^3 Platelet count ≥ 100,000/mm^3 No evidence bleed diathesis Aspartate aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 2.5 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>